A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

NCT07187115 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 699

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).

Conditions

  • Atrial Fibrillation (AF)
  • Persistant Atrial Fibrillation

Interventions

DEVICE

FARAPOINT Pulsed Field Ablation System

A component of the FARAPULSE Pulsed Field Ablation (PFA) System and is a multi-electrode bidirectional, deflectable percutaneous catheter, an adjunctive catheter designed to create focal-type lesions for the creation of an ablation line between the inferior vena cava and the tricuspid valve.

DEVICE

OptiMap System (non-ablative)

An electrophysiology mapping system that uses a proprietary algorithm to analyze electrogram signals.

DEVICE

FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

All subjects will undergo electroanatomical mapping of the entire left atrium with the FARAWAVE NAV Catheter and Opal HDx Mapping System, followed by PFA PVI with the FARAWAVE NAV PFA Catheter, per the instructions of use.

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-07
Primary Completion
2028-07-31
Completion
2030-12-31
FDA Device
Yes

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Netherlands
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07187115 on ClinicalTrials.gov